According to Zacks, “CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The company’s BioGlue surgical adhesive, the company marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The company also manufactures CryoLife- O’Brien and CryoLife-Ross stentless porcine heart valves which are distributed within the European Community. (PRESS RELEASE) “
Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity reissued a buy rating on shares of CryoLife in a research report on Tuesday, July 26th. Lake Street Capital started coverage on shares of CryoLife in a research report on Wednesday, June 15th. They set a buy rating and a $15.00 price objective for the company. Finally, Piper Jaffray Cos. reissued an overweight rating and set a $16.00 price objective on shares of CryoLife in a research report on Wednesday, July 27th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $15.00.
Shares of CryoLife (NYSE:CRY) opened at 16.95 on Tuesday. CryoLife has a 52-week low of $8.94 and a 52-week high of $18.64. The firm has a 50 day moving average price of $17.12 and a 200-day moving average price of $13.58. The company has a market cap of $578.16 million, a price-to-earnings ratio of 54.33 and a beta of 1.05.
CryoLife (NYSE:CRY) last issued its quarterly earnings data on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.11. CryoLife had a net margin of 5.80% and a return on equity of 8.15%. The firm earned $47.10 million during the quarter, compared to the consensus estimate of $35.50 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The company’s revenue for the quarter was up 32.6% compared to the same quarter last year. Equities research analysts anticipate that CryoLife will post $0.34 earnings per share for the current year.
In related news, Director C Elkins Ronald sold 2,000 shares of the company’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total value of $28,000.00. Following the completion of the transaction, the director now owns 103,586 shares of the company’s stock, valued at approximately $1,450,204. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.08% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors increased its position in shares of CryoLife by 1.1% in the first quarter. BlackRock Fund Advisors now owns 1,642,615 shares of the company’s stock valued at $17,658,000 after buying an additional 18,349 shares in the last quarter. California State Teachers Retirement System increased its position in shares of CryoLife by 22.3% in the second quarter. California State Teachers Retirement System now owns 66,083 shares of the company’s stock valued at $780,000 after buying an additional 12,045 shares in the last quarter. Spark Investment Management LLC increased its position in shares of CryoLife by 217.6% in the first quarter. Spark Investment Management LLC now owns 39,700 shares of the company’s stock valued at $426,000 after buying an additional 27,200 shares in the last quarter. Royce & Associates LP increased its position in shares of CryoLife by 10.6% in the first quarter. Royce & Associates LP now owns 731,200 shares of the company’s stock valued at $7,860,000 after buying an additional 70,000 shares in the last quarter. Finally, Essex Investment Management Co. LLC purchased a new position in shares of CryoLife during the second quarter valued at $921,000. 58.13% of the stock is owned by institutional investors.
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.